TX-EMIST
2.11.2020 14:02:05 CET | Business Wire | Press release
EMist® Disinfection Solutions today announced the launch of the EX-7000 Tru Electrostatic™ Disinfectant Sprayer.
The EX-7000 is lightweight and ergonomic weighing in at just 14.9 pounds making it one-half lighter than other sprayers. Equipped with intelligent Charge Detect™ Technology, the EX-7000 electrostatic sprayer continuously detects the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue, ensuring the most comprehensive disinfectant coating in the industry, and reducing labor and chemical costs by 50 percent.
Disinfectant is first atomized, passes through an electrostatic-induction nozzle, charged using a bipolar power supply, and then discharged toward the target area. The bipolar supply causes the electrical charges to be alternatively redistributed, resulting in droplets having an excess of either positive or negative charges. These charged droplets are so attracted to the targeted area that they coat the sides, edges, and backside of surfaces.
EMist’s TruElectrostatic Disinfectant Sprayers are built on six core platforms, resulting in an electrostatic sprayer that provides 100 percent continuous electrostatic charge output, eliminates grounding, yielding superior, comprehensive coverage.
TruTechnology: EPIX Charge Detect Technology
Using EPIX Charge Detect Technology, the electrostatic sprayers continuously detect the polarity of the user and the equipment and adjusts automatically so that grounding is never an issue. The discharged droplets wrap around surfaces. This wraparound effect creates an even, consistent and comprehensive coverage of chemical, reducing chemical and labor costs.
TruConfidence: Patented. Proven. Trusted.
Since the emergence of COVID-19, many companies have appeared overnight claiming they have electrostatic sprayers. When dealing with life-threatening pathogens, it’s critically important to know that the company you’re buying from is experienced, respected, and proven. EMist electrostatic sprayers are patented, backed by independent lab studies, used during the 2014 Ebola crisis, and developed by electrostatic industry veteran Mike Sides, who frequently works with the Department of Defense, Naval Entomology Center of Excellence, USDA, and the World Health Organization.
TruCharge: Best Performance
Electrostatic sprayer polarity matters. Most surfaces have a negative or neutral charge (the earth itself is negative). Per the EPA, electrostatic sprayers should impart a positive charge so that the positively charged disinfectant droplets are attracted to targeted negative or neutral surfaces. Positively charged droplets increase droplet adhesion and wrap.
TruDesign: Safer Operation
When spraying big areas, big buildings, or tight spaces, a cordless sprayer allows you to maneuver and move about freely. EMist sprayers are ergonomic, lightweight, and cordless. That means operators can take the sprayer to where the work needs to be done rather than relying on wall outlets at the work site. Portability is a clear advantage for any user who needs to go where the work is to get the job done right.
TruAssurance: User Safety
Per the EPA, electrostatic disinfectant sprayers should have a median droplet size greater than 40 microns. Droplets must be large enough to resist evaporation and drift but small enough that the droplets can change their trajectory when it comes close to a target. Most competitor sprayers produce droplets of less than 40 microns making them highly drift-prone and increasing user inhalation concerns. EMist sprayers maintain a median droplet size of 75 microns.
TruCost: Lower Total Cost of Ownership
Based on the need to disinfect large areas, manual application of disinfectants is a thing of the past. Electrostatic application is the new normal. Customers using EMist systems typically see up to 50 percent reduction in labor and chemical costs. Competitively priced, advanced and patented electrostatic technology, and proven performance provide an overall lower total cost of ownership.
EMist has announced a reservation program for purchasers who want to secure their units in December. The company will begin taking refundable $50 reservations on its official website starting on November 2 at 8 a.m. Central Time. The EX-7000 is available through EMist distributors at a list price of $3,995 USD.
About EMist
Headquartered in Fort Worth, Texas, EMist develops intelligent electrostatic disinfectant sprayers that make spaces healthier. For more information, visit EMist.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005026/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
